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CYCLOOXYGENASE (COX) metabolizes arachidonic acid to prostaglandins (PGs) and thromboxane (20) and exists in two isoforms (23) . Constitutively expressed COX-1 is present in most tissues where it synthesizes PGs continuously to maintain physiological functions (23, 29) . In contrast, COX-2 is induced by proinflammatory stimuli, cytokines, and mitogens and synthesizes a large quantity of PGs (8, 10, 12) . COX-2 is crucial to the inflammatory response (4, 28) , and nonsteroidal antiinflammatory drugs (NSAIDs) selective for its inhibition are now used clinically to treat inflammatory arthropathies. However, evidence is now emerging to show that COX-2 is also involved in tumorigenesis. For instance, COX-2 is constitutively expressed in various cancerous cells and tissues (13, 24) , while in APC ⌬716 mice, a model of familial adenomatous polyposis bearing a COX-2 deletion, there was a dramatic reduction in intestinal polyp size and number (16) . In the same model, mice treated with a selective COX-2 inhibitor had a reduced polyp formation (19) . Indeed, epidemiological studies have demonstrated a 50% reduction in the rate of mortality from colorectal cancer in patients taking NSAIDs (6) .
It has been shown that forced COX-2 overexpression arrests rat intestinal epithelial cells at G 1 and confers resistance to apoptosis (5) . COX-2 overexpression in ECV-304 cells is associated with a decrease in cells in S phase and an accumulation in G 0 /G 1 , while in COS-7 and human embryonic kidney 293 cells there is an increase in cells in G 2 /M (26) . Additionally, H-rastransfected rat intestinal epithelial cells constitutively overexpressing COX-2 traverse the cell cycle in the absence of serum and show significantly reduced proliferation after treatment with a selective COX-2 inhibitor (21) . Collectively, these results suggest that continuous COX-2 expression causes phenotypic changes typical of cancerous cells by regulating, at least in part, cell cycle progression. However, despite the mounting evidence that pathological overexpression of COX-2 enhances proliferation and reduces apoptosis in cancerous or transformed cells, comparatively little is known about the role of transient COX-2 expression in primary cells. Therefore, in the present study we examined whether COX-2 regulates G 0 /G 1 to S phase transition and programmed cell death in human foreskin fibroblasts (HFF), a well-characterized model for cell cycle studies. Our results show that COX-2 expression after serum stimulation was restricted to the G 0 /G 1 phase of the cell cycle and that its inhibition did not alter G 0 /G 1 to S transition or result in programmed cell death.
MATERIALS AND METHODS
Cell culture. HFF were obtained from American Type Culture Collection (Manassas, VA) and cultured on 10-cm plates in DMEM supplemented with 10% fetal bovine serum (FBS), 100 g/ml streptomycin, and 100 U/ml penicillin. For all experiments, cells were washed twice with PBS and incu-bated in FBS-free medium for 24 h. FBS-free medium was replaced with medium containing 10% FBS to initiate the cell cycle. All tissue culture reagents were from Life Technologies. To evaluate the effects of COX inhibitors on cell cycle progression, NS-398 (Calbiochem), indomethacin, aspirin, or sodium salicylate (Sigma) was added with 10% FBS to G 0 cells in culture.
Cell cycle analysis. The cell cycle of the 24-h serum-starved HFF was initiated by adding 10% FBS to fresh medium. At indicated time points, cells were trypsinized, washed in icecold PBS, and fixed using ice-cold acetone-free methanol (methanol:PBS ratio was 2:1). Cellular DNA was stained with 0.01% propidium iodide (Calbiochem) in PBS containing 0.1% Triton X-100 and 0.037% EDTA followed by the addition of 100 U/ml RNase (Worthington Biochemical) to remove RNA. Samples were filtered through a 35-m nylon mesh, and the percentage of cells in sub-G 0 /G 1 , G 0 /G 1 , S, and G 2 /M phase was assessed using flow-assisted cell sorting (FACS) analysis (Becton Dickinson). Data were analyzed using ModFit software (Verity software).
Northern blotting. RNA was isolated from cultured cells by using RNA-STAT 60 (TEL-TEST; Friendswood, TX). RNA (25-30 g) was fractionated on 1% agarose and was transferred to a positively charged nylon membrane. As a COX-2 probe, agarose gel-purified, full-length, 1.9-kb COX-2 cDNA was used (31) . Hybridization and detection by autoradiography were performed according to a procedure previously reported (31) .
Western blotting. Cell pellets were lysed with PBS (pH 7.4) containing 0.1% Triton X-100, 0.01% EDTA, 1 mM phenylmethylsulfonyl fluoride, 1.5 mM pepstatin A, and 0.2 mM leupeptin. Lysates were centrifuged at 13,000 rpm for 10 min. The supernatants were boiled for 5 min with equal volumes of 2ϫ gel-loading buffer (100 mM Tris, 10% mercaptoethanol, 20% glycerol, 4% SDS, 2 mg/ml bromphenyl blue). The protein concentration of the supernatant was determined by the bicinchoninic acid assay method (Pierce Chemical). Protein (5 g) was applied to and separated on 10% SDS-polyacrylamide minigels (Hoefer Scientific Instruments) using the Laemmli buffer system and transferred to polyvinylidine difluoride membranes (Amersham Pharmacia Biotech). Nonspecific IgGs were blocked with 5% nonfat dried milk containing 1 mg/ml globulin-free bovine serum albumin and incubated with specific antibodies to COX-1 and COX-2 (both 1:1,000; Santa Cruz Biotechnology). Protein bands were detected using enhanced chemiluminescence (Amersham Pharmacia Biotech).
COX activity. Because PGE 2 is the major metabolite of COX enzyme catalysis in fibroblasts, we measured its levels in the culture medium by an enzyme immunoassay detection kit (Amersham Pharmacia Biotech). 
RESULTS

COX-2 and COX-1 expression during serum-driven cell cycle progression.
We have recently shown by flow cytometry that, after FBS deprivation for 24 h, 90% HFF were in the G 0 /G 1 phase of the cell cycle, which entered into S phase 16 h after the addition of 10% FBS, and, by 24 h, Ͼ50% of cells were in S phase (7) . These results are consistent with previous reports that the vast majority of HFF cultured in medium deprived of serum are quiescent (G 0 ) (17) . COX-2 mRNA was undetectable in quiescent cells, and, after addition of FBS, low levels were measurable at 1 and 2 h, and the level peaked at 4 h (Fig. 1A) . COX-2 mRNA levels declined thereafter, becoming barely detectable at 12 h. The COX-2 protein was also expressed in a time-dependent manner after serum addition. It peaked at 6-8 h after serum treatment and declined thereafter (Fig. 1B) . In contrast, COX-1 protein was constitutively expressed in quiescent cells, increased slightly after the addition of FBS, peaked at 12 h, and remained at the same level up to 32 h (Fig. 1C) . Thus COX-1 is involved in a housekeeping function during cell cycle progression, while COX-2 expression, which coincides with G 1 phase of the cell cycle, could play a role in cell cycle regulation. PGE 2 , the main metabolite of COX in fibroblasts, was undetectable in serum-starved cells. After addition of FBS, it became detectable at 4 h and reached a plateau at 12 h (Fig. 2A) . The accumulated PGE 2 levels in the media changed very little thereafter. To determine the relative contributions of COX-2 and COX-1 to PGE 2 synthesis by serum stimulation, quiescent cells were treated with a selective COX-2 inhibitor, NS-398, concomitant with FBS stimulation. At 10 Ϫ7 M, NS-398 inhibited PGE 2 synthesis by Ͼ95% up to 24 h ( Fig. 2A) . Indomethacin (10 Ϫ6 M), a dual COX-1/COX-2 inhibitor, also caused a marked inhibition of PGE 2 synthesis (Fig. 2B) . These results indicate that, after initiation of the cell cycle by FBS, COX-2 was responsible for synthesizing large quantities of PGE 2 during the G 1 phase of the cell cycle.
Effect of COX inhibitors on cell cycle progression and apoptosis. Expression of COX-2 and PGE 2 synthesis in the G 0 /G 1 phase of the cell cycle implicates a role for COX-2 in regulating G 0 /G 1 to S transition. To discern this, we treated quiescent cells with NS-398 at the same time as FBS stimulation. Despite an almost complete obliteration of PGE 2 synthesis by NS-398 ( Fig.  2A) , proportions of cells that progressed through G 1 and entered S phase were unaltered by this selective COX-2 inhibitor compared with the controls (Fig. 3A) . Because indomethacin was previously reported to arrest cells in G 1 (1), we also treated quiescent cells with this dual COX inhibitor in the presence of FBS but observed no change in the percentages of cells in G 0 /G 1 compared with controls (Fig. 3B) . Western blot analysis revealed that neither NS-398 nor indomethacin inhibited COX-2 protein expression (data not shown). We also evaluated the effect of aspirin, which was shown previously to inhibit COX-2 mRNA and protein levels in these cells (31), on cell cycle progression. Aspirin pretreatment had no significant effect on altering percentages of cells entering the S phase. Similarly, sodium salicylate (10 Ϫ4 M) did not change cell cycle progression (data not shown).
Evidence obtained from various transformed and cancerous cell lines suggests that COX-2 can arrest cells in either the S or G 2 /M phases of the cell cycle (26) in addition to protecting against apoptosis (27) . Therefore, we carried out experiments with both NS-398 (10 Ϫ7 to 10 Ϫ9 M) and aspirin (10 Ϫ4 to 10 Ϫ7 M) and found that COX-2 inhibition did not arrest HFF at any phase of the cell cycle or induce programmed cell death. Data representing the highest doses of each drug are shown in Fig. 4 . Apoptosis was determined by the presence/absence of a sub-G 0 /G 1 peak using propidium iodide staining by FACS analysis. For these experiments, apoptosis and cell cycle analysis were carried out at a number of critical time points after Fig. 2 . Effects of COX inhibitors on PGE 2 release from serumstimulated quiescent HFF. Cells were arrested in G 0 by serum deprivation for 24 h followed by stimulation with 10% fetal bovine serum (FBS). Effects of NS-398 (A; 10 Ϫ7 M) and indomethacin (B; 10 Ϫ6 M) on COX activity were assessed by measuring PGE 2 levels in the culture medium. Both drugs were added to the medium at the same time as FBS and were dissolved in DMSO, which, when used as a control, had no effect on PGE 2 synthesis (data not shown). Data representing means Ϯ SE from 4 experiments are shown. Open and filled bars denote absence and presence of an inhibitor, respectively. (Fig. 4) . Taken together, these results indicate that the transient expression of COX-2 and resultant PGE 2 synthesis at the G 1 phase of the cell cycle did not regulate G 1 to S transition, apoptosis, or progression of cells through either S or G 2 /M phases.
Effects of interleukin-1␤ on COX-2 induction, PGE 2 synthesis, and cell cycle progression induced by serum.
To examine further the role of COX-2 in fibroblast proliferation, we treated quiescent HFF with a combination of serum and the proinflammatory cytokine interleukin-1␤ (IL-1␤; 1 nM), a well-known inducer of COX-2 and PGE 2 synthesis. It was found that, while this combination of stimuli caused a sustained increase in COX-2 protein expression (Fig. 5A) and PGE 2 synthesis (Fig. 5B) over and above that of serum alone during G 0 /G 1 , there was no corresponding alteration in cell cycle progression into S phase (Fig. 5C) .
Platelet-derived growth factor drove the cell cycle without inducing COX-2 expression. Platelet-derived growth factor (PDGF) is known to drive quiescent cells into the cell cycle. We determined whether PDGFdriven cell cycle progression was similarly accompanied by COX-2 expression as serum. To our surprise, despite a similar time course of cell cycle progression as serum (Fig. 6A ), PDGF at a submaximal concentration (1 ng/ml) did not induce COX-2 protein expression during the 24-h period (Fig. 6B ) or increase PGE 2 synthesis (Fig. 6C) , in contrast to the reported data of COX-2 induction by PDGF at a higher concentration (10 ng/ml) (30) . Our results with submaximal concentrations of PDGF further support the notion that COX-2 expression is not essential for cell cycle progression.
DISCUSSION
In this study, we determined COX-2 expression during synchronized cell cycle progression by using a fibroblast model that has been widely used to characterize the cellular and molecular events and control mechanisms of the cell cycle (17) . We used FBS and PDGF to drive quiescent cells into the cell cycle, and the results show a striking difference in COX-2 expression. COX-2 is expressed in the G 1 phase of FBS-driven cells, whereas, in PDGF-driven cell cycle progression, COX-2 protein was undetectable up to 32 h after PDGF treatment. These results suggest that COX-2 expression is not an integral part of cell cycle progression but rather is induced in G 0 cells by FBS, which is coincidental with the G 0 phase of the cell cycle. It is possible that cell cycle progression and COX-2 expression are induced by different factors in FBS. IL-1␤ greatly increases COX-2 expression and PGE 2 production induced by serum but has no effect on serum-driven cell cycle progression, despite the production of large quantities of PGE 2 . We have recently shown that addition of IL-1␤ alone without FBS to quiescent fibroblasts does not drive the quiescent cells into the cell cycle, and yet it induces COX-2 expression (7). These results support the notion that cells in G 0 phase are highly responsive to exogenous stimuli in COX-2 expression. Taken together, these results suggest that COX-2 expression is not inherently tied to cell cycle progression but is an important property of G 0 cells in response to exogenous stimuli including serum, IL-1␤, and phorbol esters.
Our results further suggest that COX-2 expression is not essential for cell cycle progression. Selective inhibition of COX-2 with NS-398 obliterates almost the entire PGE 2 synthesis without changing the duration of G 1 and the proportion of cells that enter the S phase of the cell cycle. Aspirin, which inhibits COX-1/COX-2 activities and suppresses COX-2 expression (31), also has no effect on the cell cycle. This is further supported by cell cycle progression induced by PDGF despite a lack of COX-2 induction or PGE 2 synthesis. Thus our results are in striking contrast to those from persistent transfection of COX-2, which causes cell cycle arrest. One possible explanation for the difference is that persistent COX-2 overexpression during the S and G 2 /M phases of the cell cycle causes DNA damage, which signals cell cycle arrest. It has been reported that proliferative cells are more susceptible to DNA damage and mutation (2) . COX-2 overexpression is accompanied by generation of metabolites, including malondialdehyde, which causes oxidative stress to DNA (18) , and inhibition of COX-2 by nebutame in asynchronized cells, which reduces the level of DNA oxidation (25) . We have recently observed that that COX-2 expression in response to phorbol 12-myristate 13-acetate and IL-1␤ is subdued in proliferative fibroblasts compared with quiescent cells (7) . These results suggest that COX-2 expression is controlled in a cell cycle-dependent manner in normal cells. Under the control mechanism, COX-2 is transiently expressed predominantly in cells at quiescent or early G 1 of the cell cycle. Work is in progress to elucidate the control mechanism.
It was reported that indomethacin induces G 1 arrest and causes apoptosis in both COX-2-positive and COX-2-negative cell lines (22) , as well as induces apoptosis in transformed murine fibroblasts in the absence of both COX isoforms (32) . Indomethacin has been shown to bind and activate peroxisome proliferator-activated receptor-␥ (PPAR␥) (14) , a nuclear receptor that, when activated in human colorectal cancer cell lines, causes G 1 arrest and apoptosis (3) . However, in the present study, indomethacin had no effect on either cell cycle progression or apoptosis in nontransformed primary HFF. It may be speculated that activation of the PPAR␥ is also without effect on cellular proliferation and programmed cell death in HFF. Thus there are striking differences in response to indomethacin between normal and transformed cells. These differences may reflect derangements of the endogenous control of COX-2-dependent and COX-2-independent cell cycle arrest, apoptosis resistance, and cell proliferation in transformed and cancer cells, in contrast to a tight control of COX-2 expression in normal cells. Transient expression of COX-2 during G 0 /G 1 phase of the cell cycle by serum is likely to play a physiological role such as wound healing. It has been shown by microarray that several genes including COX-2, transforming growth factor-␤ (TGF-␤), and metalloproteinase-1 (MMP-1) are expressed in mid G 0 /G 1 in serum-stimulated quiescent human dermal diploid fibroblasts (9) . COX-2 and PGE 2 have been reported to modulate the expression of TGF-␤ (11) and MMP-1 (15) in asynchronous cells. However, we did not observe such modulation in our synchronized fibroblast model, since NS-398 at doses reducing PGE 2 synthesis by Ͼ95% had no effect on TGF-␤ or MMP-1 levels stimulated by serum (data not shown). Our results suggest that serum stimulates quiescent cells to express COX-2 and several other genes that act in concert to promote wound healing and other pathophysiological processes.
